It's How Medicine Should Be®


French German Italian Portuguese Russian

Acamprosate Fragile X Syndrome (Ages 5-22)

Clinical Trial Title: 
Study of acamprosate in youth with fragile X syndrome versus placebo
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Elizabeth Berry-Kravis, MD
Clinical Trial Protocol Description: 

The purpose of this study is to learn more about the effectiveness of acamprosate versus placebo as a drug treatment for interfering symptoms associated with fragile X syndrome, such as irritability, hyperactivity and social impairment. This study will also help determine the amount of medicine that will be used in future treatment for children with FXS. Nationwide, 48 patients will be recruited for this study. At Rush University Medical Center, we expect to recruit approximately 24 patients. The treatment will be assigned randomly.

Clinical Trial Eligibility Criteria: 

You may be eligible to participate in this study if you:

  • Are between the ages of 5-22 with a diagnosis of fragile X syndrome
  • Are able to swallow a large-capsule medication

You will be excluded from this study if you:

  • Are taking more than two psychotropic drugs
  • Have an unstable seizure disorder or a recent change in anti-convulsant drug dosing

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Clinical Trial Area: 
Pediatric Neurological Disorders
Contact Phone: 
(312) 942-0025
Contact Name: 
Jamie Chin